论文部分内容阅读
近年研究证明抑制胆固醇合成的调速酶(3-羟-3甲基戊二酰辅酶 A 还原酶,简称 HMG CoA 还原酶)对治疗原发性高胆固醇血症和糖尿病引起的继发性高胆固醇血症非常有效。本文报道一项交叉试验,比较 HMG CoA 还原酶抑制剂 simvastatin 和消胆胺对10例长期未缓解肾病综合征患者脂蛋白的影响。对象为10例蛋白尿超过3g/24h 的肾病综合征患者,试验前总胆固醇均在8.5mmol/L 以上,年龄30～75岁。7例为男性。活检诊断膜性肾小球肾炎6
In recent years, studies have shown that the inhibition of cholesterol synthesis rate-regulating enzyme (3-hydroxy-3-methylglutaryl coenzyme A reductase, referred to as HMG CoA reductase) for the treatment of primary hypercholesterolemia and diabetes caused by secondary high cholesterol Serum is very effective. This article reports a crossover study comparing the effects of simvastatin and cholestyramine, a HMG CoA reductase inhibitor, on lipoprotein in ten patients with long-term unreceased nephrotic syndrome. The subjects were 10 patients with nephrotic syndrome with proteinuria exceeding 3g / 24h. The total cholesterol before the experiment was above 8.5mmol / L, and the age was 30-75 years old. 7 cases were men. Biopsy diagnosis of membranous glomerulonephritis 6